Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Documents similaires

• Amyloid: An evolutionarily conserved protein to fight infection or a toxic protein that causes Alzheimer's disease?
  par: Jahnavi Shriram, et autres
  Publié: (2026)
• Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
  par: Philip Scheltens, et autres
  Publié: (2026)
• APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics
  par: Susan Abushakra, et autres
  Publié: (2024)
• Time saved in activities of daily living and whole‐brain volume: Post hoc analysis of a randomized feasibility trial of gamma oscillation treatment in participants with mild or moderate Alzheimer's disease
  par: Ralph Kern, et autres
  Publié: (2025)
• Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
  par: Ronald C. Petersen, et autres
  Publié: (2025)